Alleo Labs

Alzheimer’s is personal for me. I think of my dad and his impact on my life all the time. That’s one of the reasons I’m excited about the investments we’re making to accelerate Alzheimer’s R&D, particularly by enabling more data sharing and global collaboration among researchers. Recently, our partners at the Alzheimer's Disease Data Initiative surveyed Alzheimer’s researchers at AAIC24 to learn what they’re most excited about—and what they view as the greatest barriers to progress. Their responses were interesting. Researchers are excited about the potential for new therapeutics and diagnostic tools, including blood-based biomarkers. They believe we need to break down barriers to data access, data sharing, and global research collaboration across academia, research agencies, and pharmaceutical companies to continue to drive and accelerate breakthroughs. I agree. ? The potential for AI and machine learning to speed up Alzheimer’s research is also something that excites me. In the next couple months, the ADDI will be launching applications for a fellowship cohort with this exact focus. I’m eager to see how all these efforts will help us make even more progress and eventually find a cure.?

As more clinical biomarkers become available, William H. Gates Sr. AD Fellow, Jermaine Ross, becomes more optimistic for the future of #ADRD research. As we approach #WorldAlzheimersDay, what are you most optimistic about for the future of Alzheimer’s disease research?

?What a day!? On Monday September 2nd, we got together for our annual YOD-MOLECULAR consortium meeting at Restaurant De Bosbaan in Amstelveen. We shared and discussed the progress of the work of the past few months, and had some great (international!) speakers over. Here's a short summary: ??Toon Renssen, Ismael Luis Calandri, Roberta Giannelli, and Jimmy Mulder presented project updates from the four workpackages ??We finally got to meet J Ross, Ph.D. in person! Ross gave a great talk about his company Alleo Labs, where they work with AI to identify targets for therapeutic interventions in #AD. What a pleasure to have you! ??Jetske van der Schaar led a great discussion on the important of patient involvement in translational research. From clinical to fundamental research, this is a topic that all researchers are affected by. So important to talk about! Special thanks to all of our speakers, our researchers, and everyone who attended on this sunny day, and we can look forward to so much promising work?? #YODMOLECULAR #youngonsetdementia Yolande Pijnenburg Lotte Smit Amsterdam UMC - Alzheimercentrum Amsterdam Vrije Universiteit Amsterdam Hogeschool Utrecht Alleo Labs Winterlight Labs Hersenstichting Rijksuniversiteit Groningen Erasmus MC Leiden University Medical Center Alzheimer Nederland Team Alzheimer Kenniscentrum Dementie op Jonge Leeftijd FTD Lotgenoten Nederlands Geheugenpoli Netwerk NWO (Nederlandse Organisatie voor Wetenschappelijk Onderzoek)

Winning is the oldest strategy. These days, feels like we have more wins than losses on our mission to treat Alzheimer’s and other dementias. Want to thank the folks at the Alzheimer's Disease Data Initiative for putting on a fantastic list of events for the William H. Gates, Sr. AD fellows, and to everyone who made it out to the wonderful reception. Speaking of which, the Alzheimer’s Impact Alliance reception was truly inspiring, seeing all the major players under a single roof, including Dolby Family Ventures, Cure Alzheimer's Fund, BrightFocus Foundation, F-Prime Capital, EQT Group, Gates Ventures, Alzheimer's Drug Discovery Foundation, and SV Dementia Discovery Fund (DDF). ?? #AAIC24 Highlights: ??Lund University found that the PrecivityAD2 blood test was about 90% accurate at identifying Alzheimer’s. Now compared that with dementia care and primary care docs at 73% and 63% accuracy, respectively. ??Spoke with practitioners that are actually administering Leqembi to their patients. To quote one neurologist, “I told my patient, look, if you want to do this, we’ll do this together.” ??? Maria Carrillo, Chief Science Officer of the Alzheimer's Association, highlighted that a subgroup of participants in the EVOKE+ trial are taking both FDA-approved Leqembi AND Ozempic, marking a groundbreaking approach. Leqembi effectively removes amyloid from the brain, while Ozempic is believed to reduce inflammation. Novo Nordisk anticipates the Phase 3 trial results in 2025. ?? More GLP-1 in your coffee? Novo Nordisk announced that Liraglutide, another GLP-1 agonist, may also be effective at slowing decline in cognitive function after one year of treatment. Your move, Lilly. ??? Congrats to RetiSpec on closing their $10M Series A! Just an incredible company! ??Biogen and Denali Therapeutics are ending the development of a method to shuttle amyloid antibodies into the brain. Dubbed ATV:Aβ, the technology aimed to increase brain exposure and target engagement of anti-amyloid therapies, potentially reducing amyloid-related imaging abnormalities. See everybody next year in Toronto! ????

Thank you Phyllis Ferrell for moderating this fantastic panel with the first cohort of William H Gates Sr Fellows, a program of the Alzheimer's Disease Data Initiative. A bright and early start to an already long week at #AAIC24. Thank you for the support Susan Kohlhaas Miia Kivipelto John Gallacher (PhD AFBPsS CPsychol FFPH) Lefkos Middleton Richard Mohs Pieter Jelle Visser Eric Reiman Takeshi Iwatsubo Sarah Lenz Lock, JD

Meet Jermaine Ross, a Gates Sr. AD fellow, CEO and Co-Founder of Alleo Labs, and Alzheimer’s Association board member. Dr. Ross received his Ph.D. in neuroscience from Brown University. His research focuses on Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease. #2023GatesFellows bit.ly/3Ya0hVG

The BIO International Convention in San Diego last week was eventful and rejuvenating. ?? It was great to see several talks on precision psychiatry and innovation in neuroscience. The Kernel x Focalpoint Partners Frontiers in Precision Neuromedicine side event was fantastic. Bringing together thoughts leaders, investors, founders, and pharmaceutical industry professionals all intersted in neuroscience was quite special. We appreciate all of those who came and made our event a space for intellectual discourse and socializing away from the business of BIO. At Kernel, Ryan Field and I are seeking to connect with pharmaceutical partners intersted in learning more about Kernel Flow. At Focalpoint Partners, Brom Rector, CFA and I are looking to invest in early stage companies developing devices, therapeutics and other tech, to ameliorate problems in the CNS. ?? We look forward to putting on more of these events in Los Angeles and other places this year, continuing to foster the intersection of neurotechnology and neurotherapeutics! Stay tuned and reach out if interested in learning about future programming.

Kernel and Focalpoint Partners are hosting two interactive day sessions and a networking reception on Wednesday June 5 in San Diego next week. Some talk titles include: ? Enabling Real World Precision Neuromedicine ? AI in Precision Medicine for Neurodegeneration ? Happy Mito = Health Brain ? New Chemical Entities in Neuropsychiatry ? CNS Pipelines and M&A We have quite a bit of exciting programming and impressive people joining us. >>> Request to join here: https://lnkd.in/gVMWpA9U ?? Feel free to share with your friends in neuro! Ryan Field Brom Rector, CFA Rebecca Baken

?? Alleo Labs will be at AD/PD 2024 in Lisbon. See you next week, my friends!